Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Intensive Chemotherapy in Acute Myeloid Leukemia
NCT06635681Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Event-free survival up to 2 years. Started Sep 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06635681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635681.